Guildford, UK, April 10, 2006 - IDBS today announced that Pfizer Global R&D has licensed the IDBS BioBookTM global electronic experiment and study management software. BioBook is being deployed across the full spectrum of research biology; including discovery biology, worldwide safety sciences, pharmacokinetics dynamics and metabolism, and secondary and safety pharmacology. Users of BioBook can manage every aspect of their complex late stage research. As part of the global contract, BioBook will be used across all of Pfizer’s research sites worldwide, with IDBS delivering implementation and support services.

About BioBook Software

· From design and set-up through data capture, analysis and graphing to report creation, sign-off and publication - BioBook manages the entire lifecycle of a complex biological experiment in one place

· All data can be easily and securely recorded in a 21 CFR Part 11 compliant environment

· BioBook enables real-time data sharing, analysis and rapid delivery of reports

· BioBook is the leading commercially available solution for complete electronic experiment and study management in a single secure environment

Over two hundred life science R&D organisations around the world use IDBS enterprise data management solutions to drive their research, including 18 of the top 20 pharmaceutical and biotechnology companies.

###

About IDBS
IDBS is a leading provider of integrated software solutions to the life sciences industry. Maximizing the value of research data, IDBS enables organisations to capture, store, share and use data efficiently and effectively while protecting intellectual property across the spectrum of discovery activities.

Headquartered in Guildford, UK, IDBS has U.S. offices in California, New Jersey and Massachusetts. IDBS partners with CTC Laboratory Systems in Japan and a network of distributors to market IDBS products and services in Asia. Founded in 1989, IDBS employs more than 150 people worldwide. For more information, visit: http://www.idbs.com/ .